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Figure 2. Survival by Retrospective High Resolution HLA Match.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S66Comparison of 3 HR subgroups (<4/8 vs >¼4/8, <5/8 vs
>¼5/8, <6/8 vs >¼6/8 allelic matches) showed signiﬁcant
reduction in mortality from any cause and non-relapse/
non-disease progression mortality in transplants matched at
>¼6/8 versus <6/8 alleles (p ¼ 0.02 and 0.01, respectively).
Although decreased in incidence, there was no signiﬁcant
association for graft failure, GVHD or infections. In subgroup
comparison using original HLA typing (<3/6 vs >¼3/6, <4/6
vs>¼4/6,<5/6 vs>¼5/6 matches), a signiﬁcant reduction in
mortality from any cause and non-relapse/non-disease
progression mortality was seen in those matched at >¼5/6
versus <5/6 loci (p¼0.05 and 0.01, respectively). Screening
for class I and II AHA was available in 27 patients and was
positive in 8/14 patients with primary graft failure and 3/13
who engrafted. Results were not available for 30/43
engrafters and 5/19 non-engrafters.
Conclusion: HR typing showed an increase in HLA recipient
cord disparity in comparison to standard typing. We
validated the current standard for UCB selection as >¼5/6
grafts were associated with signiﬁcantly improved overall
survival (see Figure 1), which was shown in our >¼6/8 HR
matches as well (see Figure 2). The role of AHA in graft
failure needs to be further tested. In choosing donors for
UCBT, we recommend choosing >¼6/8 HR match especially
when >¼5/6 UCB grafts are available and if able, taking
into account AHA.51
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Out of an estimated 20,000 patients requiring an alloge-
neic HCT in India, only 500 odd patients receive one. Keeping
in cognizance the resource constraints, the major reason for
the discordance lies in the lack of alternate donors. Whilst
unrelated donor marrow and cord sufﬁce for the ethnicmajorities in Europe and the USA, such registries provide for
less than 10% of HCT recipients due to both cost and an
available match. With this background, we initiated a
Haploidentical Family Donor HCT program in 2011.
In our initial screening of 50 patients referred for an
allogeneic BMT, a matched family donor was available in 11
patients and a suitable Haploidentical family donor was
available for 49, whereas a fully matched unrelated donor
(10/10) was available for none. Hence we decided to develop
a Haploidentical BMT program within the available
resources. We chose a Posttransplant Cyclophosphamide
(PTCY) based approach with PBSC as the graft source.
We have carried out 40 transplants in 32 patients over the
last 3 years (AML-15; ALL-2; CML-BC-2; Lymphoma-2;
Severe Aplastic Anemia (SAA)-10; Thalassemia-1). All
received PBSC with PTCY on days 3 and 4 followed by
cyclosporine and MMF. The conditioning regimen comprised
of Fludarabine 150 mg/CY-30 mg/Melphalan-100 mg (SAA)
or 120-140 mg (others) with Fludarabine and IV Busulfan
(6.4-9.6 mg/kg) or Treosulfan 10-12 gm/m2. 2GY TBI was
offered to 4 patients instead of Melphalan. Sirolimus
was added later on day -7 pretransplant to the last 5 patients
with SAA.
30/32 patients surviving beyond 21 days had successful
engraftment with full donor chimerism, including 10/11 pa-
tients with SAA and Thalassemia. 6/8 evaluable patients un-
dergoing a second Haploidentical HCT engrafted as well.
Acute GVHD grade 2-4 developed in 3/32 patients. Day 100
NRM was 5/32 (15%) and the overall survival at 2 years
was 55%. The major cause of NRM was infection with
Carbapenem-resistant Gram Negative Bacilli accounting for
90% of the deaths. Chronic GVHD occurred in 10% of the
evaluable patients. With stringent monitoring for CMV and
preemptive therapy, only 1 patient succumbed to CMV
disease. The outcome and cost of this extremely high risk
group of patients were comparable to matched family donor
BMT. PBSC as graft sourcewas associatedwith a low incidence
of both acute and chronic GVHD.We also studied the effect of
Natural Killer Cell Ligand Mismatch (NKLMM) donor on the
outcome in all our patients. NKLMM was associated with
reduced incidence of relapse in patients with hematological
malignancies (p¼0.03). However, NKLMM donor was asso-
ciated with poor outcome in patients with SAA (p¼0.05).
In summary, Haploidentical HCT based on PTCY and PBSC
graft is feasible and probably the most viable form of
alternate donor HCT in resource constrained settings with
outcomes comparable to matched donor HCT.52
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Background: Mismatched unrelated donor (MMURD)
transplantation is widely used in patients who lack a
matched unrelated donor (MUD). Despite several published
observational studies, the magnitude of risk associated with
9 out of 10 MMURD transplant and that of HLA-speciﬁc
mismatches is still unclear. We performed a meta-analysis to
